Kiniksa Pharmaceuticals International plc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
KNSA$98.76+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
| ITEM 9B. | OTHER INFORMATION. |
|---|
Trading Arrangements.
The following table shows the “Rule 10b5-1 trading arrangements” or “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted, amended or terminated by our directors and officers during the three months ended December 31, 2024:
| · · · · Trading Arrangement · · | |||||||
|---|---|---|---|---|---|---|---|
| Name | Title | Action | Effective Date | Rule 10b5-1 | Non Rule 10b5-1 | Scheduled Expiration Date of Trading Plan(1) | Maximum Shares Subject to Trading Plan |
| Ross Moat | SVP, Chief Commercial Officer | Adoption | November 13, 2024 | X | | April 17, 2026 | 138,379 |
| (1) | A trading arrangement may expire on an earlier date if all contemplated transactions are completed before such trading arrangement’s expiration date, upon termination by broker or the holder of the trading arrangement or as otherwise provided in the trading arrangement. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.